Use of a selective enzymatic debridement agent (Nexobrid®) for wound management: Learning curve

Table 1 Patients treated with Nexobrid® (January 2015-January 2016)

Patient	Age	Sex	Etiology	Extension(%)	Depth	Time to escarectomy (d)	Treated area	Predebridement dressing	Postdebridement dressing	Surgery	Time to complete healing (d)
1	24	W	Scald	2	DPT	4	Foot	SSD	Mepitel one	Yes	35
2	31	M	Flame	20	SPT and DPT	1	Hands and lower limbs	SSD	Mepitel one	No	21
3	33	M	Flame	60	DPT and FT	0	Trunk and upper limbs and foot	SSD	Mepitel one	Yes	15
4	46	M	Chemical	6	DPT and FT	4	Trunk	SSD	Biobrane	Yes	19
5	90	M	Flame	4	DPT and FT	2	Forearm and foot	SSD	Suprathel	Yes	33
6	58	M	Flame	53	DPT and FT	0	Hands and lower limbs	SSD	Biobrane	Yes	Exitus
7	18	W	Scald	2	SPT and DPT	1	Lower limbs	WD	Suprathel	Yes	30
8	64	M	Scald	10	MPT	3	Lower limbs	SSD	Suprathel	No	14
9	58	M	Contact	1	SPT and DPT	3	Foot	WD	Suprathel	Yes	20
10	44	M	Deflagration	15	SPT and DPT	1	Upper limbs	WD	Suprathel	No	27
11	69	M	Deflagration	8	SPT and DPT	4	Upper limbs	WD	Suprathel	No	21
12	51	M	Scald	2	SPT and DPT	2	Upper limbs	Nitrofurazone	Biobrane	Yes	51
13	21	M	Flame	10	SPT and DPT	1	Upper limbs	WD	Aquacel Ag	No	16
14	56	M	Flash	5	MPT and DPT	4	Hands	WD	Suprathel	No	19
15	40	M	Deflagration	6	SPT and DPT	2	Upper limbs	WD	SSD	No	22
16	94	W	Flame	10	DPT and FT	4	Trunk and upper limbs	WD	SSD	Yes	21
17	81	M	Flame	2	SPT and FT	2	Lower limb	WD	WD	Yes	31
19	72	W	Deflagration	14	MPT	1	Lower limbs	WD	Suprathel	Yes	27
20	38	M	Deflagration	7	DPT	1	Hands	WD	Biobrane	Yes	38
21	63	M	Flame	65	MPT and FT	0	Lower limbs	SSD change to WD before 24 h	Mepitel and Nitrofurazone	Yes	23
22	46	W	Scald	4	MPT	2	Lower limb	WD	Suprathel	No	37
23	62	M	Flame	18	SPT and DPT	1	Upper and lower limbs	WD	Aquacel Ag	Yes	36
24	56	M	Flame	28	SPT and DPT	2	Lower limbs	WD	SSD	Yes	EXITUS
25	38	W	Abrasion	1	DPT	2	Hand	WD	Aquacel Ag	No	17

SPT: Superficial partial thickness; MPT: Mid partial thickness; DPT: Deep partial thickness; SSD: Silver sulfadiazine; WD: Wet dressing; W: Women; M: Man.